ARCH Venture Management, LLC Q4 2025 Filing
Filed February 17, 2026
Portfolio Value
$651.7M
Holdings
9
Report Date
Q4 2025
Filing Type
13F-HR
All Holdings (9 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | MAZEMAZE THERAPEUTICS INC. | 4,120,053 | $170.7M | 26.19% | |
| 2 | BEAMBEAM THERAPEUTICS INC. | 4,540,132 | $125.9M | 19.31% | |
| 3 | RAPPRAPPORT THERAPEUTICS INC. | 3,728,738 | $113.1M | 17.36% | |
| 4 | LYELLYELL IMMUNOPHARMA INC. | 2,759,072 | $84.9M | 13.03% | |
| 5 | VIRVIR BIOTECHNOLOGY INC. | 12,916,663 | $77.9M | 11.95% | |
| 6 | ERASERASCA INC. | 11,055,554 | $41.1M | 6.31% | |
| 7 | GOSSGOSSAMER BIO INC. | 8,055,916 | $25.0M | 3.83% | |
| 8 | TXG10X GENOMICS INC. | 737,539 | $12.0M | 1.85% | |
| 9 | QTTBQ32 BIO INC. | 320,482 | $1.1M | 0.16% |